Darotropium (bromide)

Darotropium bromide (GSK233705), a long-acting muscarinic antagonist and an inhaled anticholinergic, can be used for the research of chronic obstructive pulmonary disease (COPD) [1][2].

Product Specifications

CAS Number

850607-58-8

Product Name Alternative

GSK233705

UNSPSC

12352005

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/darotropium-bromide.html

Smiles

[H][C@]1(CC(C2=CC=CC=C2)(C#N)C3=CC=CC=C3)C[C@]4([H])[N+](C)(C)[C@@]([H])(CC4)C1.[Br-]

Molecular Formula

C24H29BrN2

Molecular Weight

425.40

References & Citations

[1]Jutta Beier, et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Int J Chron Obstruct Pulmon Dis. 2012:7:153-64.|[2]Eric Bateman, et al. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clin Respir J. 2012 Oct;6 (4) :248-57.